WuXi Biologics Named to Hang Seng Corporate Sustainability Benchmark Index

Reuters
2025/10/22
WuXi Biologics Named to <a href="https://laohu8.com/S/HSNGF">Hang Seng</a> Corporate Sustainability Benchmark Index

WuXi Biologics (Cayman) Inc. announced its inclusion in the 2025 Hang Seng Corporate Sustainability Benchmark Index, marking it as the only pharmaceutical industry company selected for this listing. The company has also been previously included in the HSI ESG Index and the Hang Seng ESG 50 Index. The selection recognizes publicly listed companies with notable ESG performance, based on an annual sustainability assessment conducted by the Hong Kong Quality Assurance Agency. WuXi Biologics reports ongoing engagement with the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, and its greenhouse gas emissions-reduction targets have been approved by the Science Based Targets initiative. The company has received several sustainability ratings and recognitions from organizations including MSCI, EcoVadis, Dow Jones Sustainability Indices, CDP, Sustainalytics, FTSE4Good, and ISS ESG.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN03088) on October 22, 2025, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10